Evidence map›Paper›PMID 36444680›Full record

ArticleEndocrinology, diabetes & metabolism2023

Evaluation of ABCA1 gene polymorphism as a prognostic index of fibrosis progression in NAFLD patients.

Samar E Ghanem, Maha M Elsabaawy, Mervat M Abdelkareem, Marwa L Helal, Warda Othman, Mahitab Elsayed, Dalia M Elsabaawy, Ashraf El Fert

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, diabetes & metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Samar E GhanemDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.
Maha M ElsabaawyDepatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.ORCID 0000-0002-3110-1547
Mervat M AbdelkareemDepatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.
Marwa L HelalDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.
Warda OthmanDepatment of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.
Mahitab ElsayedDepartment of Clinical pharmacy, Faculty of Pharmacy, Modern technology for technology and information university, Shebeen El-Koum, Egypt.
Dalia M ElsabaawyDepartment of Clinical pharmacy, Faculty of Pharmacy, Menoufia University, Shebeen El-Koum, Egypt.
Ashraf El FertDepartment of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University, Shebeen El-Koum, Egypt.
Menoufia University · EGModern University for Information and Technology · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIt had been evident that non-alcoholic fatty liver disease (NAFLD) is the new era epidemic. Despite emergence of many drugs on the pipeline that considered candidates to cure NAFLD/NASH, the critical need for defining the cohort liable to fibrosis progression is yet unmet.

aimEvaluate ABCA1 (rs1800977) genotyping as a noninvasive predictor of liver fibrosis severity. MATERIALS AND

methodsThis study included 118 liver biopsy-proven NAFLD-patients. According to Metavir-fibrosis-staging, cases were divided to early fibrosis (74 cases), and 44 cases with significant fibrosis (>F2), added to 49 healthy control subjects. All patients were subjected to liver function tests, lipids profile, triglyceride TG index, and hepatic steatosis index (HSI) and real-time PCR ABCA1 SNP (rs1800977).

resultsSignificant differences in transaminases (p > .05), albumin (p < .009), cholesterol (p0.03), low density lipoproteins (LDL) (0.006), triglycerides (p < .001), HSI (p < .001), FIB4 (p < .001) and APRI (p < .001) were reported in those with significant than early fibrosis and control groups. CC was the most prevalent in significant (36.4%) than early fibrosis (13.5%) and control groups (8.2%), with prevalence of C allele in significant fibrosis (p ≤ .003). Univariate analysis revealed that DM (p ≤ .001), TG index (p ≤ .022), cholesterol (p ≤ .03), HSI (p ≤ .006), LDL (p ≤ .02), HDL (p ≤ .01), APRI (p ≤ .02) and CC genotype (p ≤ .005) were the main factors affecting fibrosis progression in NAFLD. However multivariate analysis proved only the role of HSI (p ≤ .005), LDL (p ≤ .02), HDL (p ≤ .003) and CC genotype (p ≤ .03) in predicting fibrosis severity.

conclusionDyslipidemias, hepatic steatosis index and ABCA1 (rs1800977) gene polymorphism CC genotype; were the only independent predictors of advanced fibrosis in NAFLD-patients.

Indexed as

Non-alcoholic Fatty Liver DiseaseATP Binding Cassette Transporter 1CholesterolHumansLiver CirrhosisPolymorphism, GeneticPrognosisTriglyceridesABCA1 protein, humanATP Binding Cassette Transporter 1CholesterolTriglyceridesABCA1fibrosisnonalcoholic fatty liver diseasesingle nucleotide polymorphism

Identifiers

PMID36444680
PMCPMC9836255
OpenAlexW4310219159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.